C5a receptor

From Wikipedia, the free encyclopedia
Jump to: navigation, search
C5AR1
Identifiers
Aliases C5AR1, C5A, C5AR, C5R1, CD88, complement component 5a receptor 1, C5a receptor, complement C5a receptor 1
External IDs MGI: 88232 HomoloGene: 20413 GeneCards: C5AR1
Gene location (Human)
Chromosome 19 (human)
Chr. Chromosome 19 (human)[1]
Chromosome 19 (human)
Genomic location for C5AR1
Genomic location for C5AR1
Band 19q13.32 Start 47,290,023 bp[1]
End 47,322,066 bp[1]
RNA expression pattern
PBB GE C5AR1 220088 at fs.png
More reference expression data
Orthologs
Species Human Mouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001736

NM_001173550
NM_007577

RefSeq (protein)

NP_001727

NP_001167021
NP_031603

Location (UCSC) Chr 19: 47.29 – 47.32 Mb Chr 19: 16.25 – 16.26 Mb
PubMed search [3] [4]
Wikidata
View/Edit Human View/Edit Mouse

The C5a receptor also known as complement component 5a receptor 1 (C5AR1) or CD88 (Cluster of Differentiation 88) is a G protein-coupled receptor for C5a. It functions as a complement receptor.[5] C5a receptor modulates inflammatory responses, obesity, development and cancers.[6][7][8]

C5a receptor structure and its residues possessing role in ligand binding or signaling.

Cells[edit]

The C5a receptor is expressed on:[9]

Agonist and antagonists[edit]

Potent and selective agonist and antagonists for C5aR have been developed.[10][11][12][13]

See also[edit]

References[edit]

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000197405 - Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000049130 - Ensembl, May 2017
  3. ^ "Human PubMed Reference:". 
  4. ^ "Mouse PubMed Reference:". 
  5. ^ Gerard C, Gerard NP (1994). "C5A anaphylatoxin and its seven transmembrane-segment receptor". Annual Review of Immunology. 12: 775–808. PMID 8011297. doi:10.1146/annurev.iy.12.040194.004015. 
  6. ^ Brennan FH, Gordon R, Lao HW, Biggins PJ, Taylor SM, Franklin RJ, Woodruff TM, Ruitenberg MJ (April 2015). "The Complement Receptor C5aR Controls Acute Inflammation and Astrogliosis following Spinal Cord Injury". The Journal of Neuroscience. 35 (16): 6517–31. PMID 25904802. doi:10.1523/JNEUROSCI.5218-14.2015. 
  7. ^ Lim J, Iyer A, Suen JY, Seow V, Reid RC, Brown L, Fairlie DP (February 2013). "C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling". FASEB Journal. 27 (2): 822–31. PMID 23118029. doi:10.1096/fj.12-220582. 
  8. ^ Markiewski MM, DeAngelis RA, Benencia F, Ricklin-Lichtsteiner SK, Koutoulaki A, Gerard C, Coukos G, Lambris JD (November 2008). "Modulation of the antitumor immune response by complement". Nature Immunology. 9 (11): 1225–35. PMC 2678913Freely accessible. PMID 18820683. doi:10.1038/ni.1655. 
  9. ^ Klos A, Wende E, Wareham KJ, Monk PN (January 2013). "International Union of Basic and Clinical Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors". Pharmacological Reviews. 65 (1): 500–43. PMID 23383423. doi:10.1124/pr.111.005223. 
  10. ^ Wong AK, Finch AM, Pierens GK, Craik DJ, Taylor SM, Fairlie DP (August 1998). "Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a". Journal of Medicinal Chemistry. 41 (18): 3417–25. PMID 9719594. doi:10.1021/jm980065. 
  11. ^ Gong Y, Barbay JK, Buntinx M, Li J, Wauwe JV, Claes C, Lommen GV, Hornby PJ, He W (July 2008). "Design and optimization of aniline-substituted tetrahydroquinoline C5a receptor antagonists". Bioorganic & Medicinal Chemistry Letters. 18 (14): 3852–5. PMID 18595693. doi:10.1016/j.bmcl.2008.06.059. 
  12. ^ Sumichika H, Sakata K, Sato N, Takeshita S, Ishibuchi S, Nakamura M, Kamahori T, Ehara S, Itoh K, Ohtsuka T, Ohbora T, Mishina T, Komatsu H, Naka Y (December 2002). "Identification of a potent and orally active non-peptide C5a receptor antagonist". The Journal of Biological Chemistry. 277 (51): 49403–7. PMID 12384495. doi:10.1074/jbc.M209672200. 
  13. ^ Seow V, Lim J, Cotterell AJ, Yau MK, Xu W, Lohman RJ, Kok WM, Stoermer MJ, Sweet MJ, Reid RC, Suen JY, Fairlie DP (April 2016). "Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists". Scientific Reports. 6 (1): 24575. PMC 4837355Freely accessible. PMID 27094554. doi:10.1038/srep24575. 

Further reading[edit]

  • Sengeløv H (1996). "Complement receptors in neutrophils". Critical Reviews in Immunology. 15 (2): 107–31. PMID 8573284. doi:10.1615/critrevimmunol.v15.i2.10. 
  • Beil WJ, Schulz M, Wefelmeyer U (July 2000). "Mast cell granule composition and tissue location--a close correlation". Histology and Histopathology. 15 (3): 937–46. PMID 10963136. 
  • Yamamoto T (January 2007). "Roles of the ribosomal protein S19 dimer and the C5a receptor in pathophysiological functions of phagocytic leukocytes". Pathology International. 57 (1): 1–11. PMID 17199736. doi:10.1111/j.1440-1827.2007.02049.x. 
  • Bao L, Gerard NP, Eddy RL, Shows TB, Gerard C (June 1992). "Mapping of genes for the human C5a receptor (C5AR), human FMLP receptor (FPR), and two FMLP receptor homologue orphan receptors (FPRH1, FPRH2) to chromosome 19". Genomics. 13 (2): 437–40. PMID 1612600. doi:10.1016/0888-7543(92)90265-T. 
  • Gerard NP, Gerard C (February 1991). "The chemotactic receptor for human C5a anaphylatoxin". Nature. 349 (6310): 614–7. PMID 1847994. doi:10.1038/349614a0. 
  • Boulay F, Mery L, Tardif M, Brouchon L, Vignais P (March 1991). "Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells". Biochemistry. 30 (12): 2993–9. PMID 2007135. doi:10.1021/bi00226a002. 
  • Wahl SM, Allen JB, Gartner S, Orenstein JM, Popovic M, Chenoweth DE, Arthur LO, Farrar WL, Wahl LM (May 1989). "HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes". Journal of Immunology. 142 (10): 3553–9. PMID 2541200. 
  • Foreman KE, Vaporciyan AA, Bonish BK, Jones ML, Johnson KJ, Glovsky MM, Eddy SM, Ward PA (September 1994). "C5a-induced expression of P-selectin in endothelial cells". The Journal of Clinical Investigation. 94 (3): 1147–55. PMC 295185Freely accessible. PMID 7521884. doi:10.1172/JCI117430. 
  • Giannini E, Brouchon L, Boulay F (August 1995). "Identification of the major phosphorylation sites in human C5a anaphylatoxin receptor in vivo". The Journal of Biological Chemistry. 270 (32): 19166–72. PMID 7642584. doi:10.1074/jbc.270.32.19166. 
  • Buhl AM, Osawa S, Johnson GL (August 1995). "Mitogen-activated protein kinase activation requires two signal inputs from the human anaphylatoxin C5a receptor". The Journal of Biological Chemistry. 270 (34): 19828–32. PMID 7649993. doi:10.1074/jbc.270.34.19828. 
  • Wennogle LP, Conder L, Winter C, Braunwalder A, Vlattas S, Kramer R, Cioffi C, Hu SI (July 1994). "Stabilization of C5a receptor--G-protein interactions through ligand binding". Journal of Cellular Biochemistry. 55 (3): 380–8. PMID 7962171. doi:10.1002/jcb.240550316. 
  • Gerard NP, Bao L, Xiao-Ping H, Eddy RL, Shows TB, Gerard C (February 1993). "Human chemotaxis receptor genes cluster at 19q13.3-13.4. Characterization of the human C5a receptor gene". Biochemistry. 32 (5): 1243–50. PMID 8383526. doi:10.1021/bi00056a007. 
  • Ames RS, Li Y, Sarau HM, Nuthulaganti P, Foley JJ, Ellis C, Zeng Z, Su K, Jurewicz AJ, Hertzberg RP, Bergsma DJ, Kumar C (August 1996). "Molecular cloning and characterization of the human anaphylatoxin C3a receptor". The Journal of Biological Chemistry. 271 (34): 20231–4. PMID 8702752. doi:10.1074/jbc.271.34.20231. 
  • Werfel T, Zwirner J, Oppermann M, Sieber A, Begemann G, Drommer W, Kapp A, Götze O (August 1996). "CD88 antibodies specifically bind to C5aR on dermal CD117+ and CD14+ cells and react with a desmosomal antigen in human skin". Journal of Immunology. 157 (4): 1729–35. PMID 8759762. 
  • Höpken UE, Lu B, Gerard NP, Gerard C (September 1996). "The C5a chemoattractant receptor mediates mucosal defence to infection". Nature. 383 (6595): 86–9. PMID 8779720. doi:10.1038/383086a0. 
  • Chen Z, Zhang X, Gonnella NC, Pellas TC, Boyar WC, Ni F (April 1998). "Residues 21-30 within the extracellular N-terminal region of the C5a receptor represent a binding domain for the C5a anaphylatoxin". The Journal of Biological Chemistry. 273 (17): 10411–9. PMID 9553099. doi:10.1074/jbc.273.17.10411. 
  • Floreani AA, Heires AJ, Welniak LA, Miller-Lindholm A, Clark-Pierce L, Rennard SI, Morgan EL, Sanderson SD (May 1998). "Expression of receptors for C5a anaphylatoxin (CD88) on human bronchial epithelial cells: enhancement of C5a-mediated release of IL-8 upon exposure to cigarette smoke". Journal of Immunology. 160 (10): 5073–81. PMID 9590258. 
  • Ottonello L, Corcione A, Tortolina G, Airoldi I, Albesiano E, Favre A, D'Agostino R, Malavasi F, Pistoia V, Dallegri F (June 1999). "rC5a directs the in vitro migration of human memory and naive tonsillar B lymphocytes: implications for B cell trafficking in secondary lymphoid tissues". Journal of Immunology. 162 (11): 6510–7. PMID 10352266. 
  • Kohleisen B, Shumay E, Sutter G, Foerster R, Brack-Werner R, Nuesse M, Erfle V (December 1999). "Stable expression of HIV-1 Nef induces changes in growth properties and activation state of human astrocytes". Aids. 13 (17): 2331–41. PMID 10597774. doi:10.1097/00002030-199912030-00004. 
  • Monk PN, Scola AM, Madala P, Fairlie DP (October 2007). "Function, structure and therapeutic potential of complement C5a receptors". British Journal of Pharmacology. 152 (4): 429–48. PMC 2050825Freely accessible. PMID 17603557. doi:10.1038/sj.bjp.0707332. 

External links[edit]